



RECEIVED

OCT 17 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

TECH CENTER 1600.2900

Re Application of: John J. SAUK

Serial No.: 09/936,565

Group Art Unit: 1646

Filed: February 4, 2002

Examiner: Unassigned

For: SURFACE LOCALIZED COLLIGIN/HSP47 IN CARCINOMA CELLS

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §§ 1.56, 1.97 and 1.98Assistant Commissioner for Patents
Washington, D. C. 20231

Sir:

CITED MATERIALS

Applicant(s) hereby disclose the information listed in the attached form PTO-1449.

- ☐ Copies of materials listed but not attached were cited in parent application Serial No. ____; see 37 C.F.R. § 1.98(d).
- ☐ Copies of materials listed but not attached were cited in an International Search Report dated ____; receipt of the International Search Report and copies of references was confirmed by the PCT International Division of the U.S. PTO in the Notice of Acceptance mailed ____.

ADDITIONAL INFORMATION**LANGUAGE**

- ☒ All listed materials are in the English language; see 37 C.F.R. § 1.98.
- ☐ Non-English language references:
- ☐ The reference(s) _____ in the English-language is (are) indicated by commercial data bases to correspond to the reference(s): _____, respectively.
- ☐ (An) English-language translation(s) of the references: _____ is (are) provided.
- ☐ A commercial English-language abstract of reference(s) _____ is (are)

parent office translated into English in pertinent part in connection with a counterpart foreign application, is provided indicating the relevance of the cited reference(s).

FEES

- ☒ No fee is required for this Information Disclosure Statement because:
 - ☐ This Information Disclosure Statement is being filed within three months of the filing date of a national application (other than a CPA) under § 1.53(d) or within 3 months of the date of entry of the national stage under § 1.491 in an international application;
 - ☒ This Information Disclosure Statement is being filed before the mailing of a first action on the merits;
 - ☐ This Information Disclosure Statement is being filed after a first action on the merits but before the mailing date of any of a final action under § 1.113, a notice of allowance under § 1.311, or an action that closes prosecution in the application, and is accompanied by a certification below.
 - ☐ This Information Disclosure Statement is filed under 37 C.F.R. § 1.97(i).
- ☐ A fee is required for this Information Disclosure Statement:
 - ☐ This Information Disclosure Statement is being filed after a first action on the merits but before the mailing date of any of a final action under § 1.113, a notice of allowance under § 1.311 or an action that closes prosecution, and is accompanied by the fee set forth in § 1.17(p).
 - ☐ This Information Disclosure Statement is being filed after the mailing date of a final rejection or a notice of allowance under § 1.311 or an action that closes prosecution, but before the payment of the issue fee, and is accompanied by the fee set forth in § 1.17(p) and a certification below.

CERTIFICATION

- ☐ Each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the undersigned, having made reasonable inquiry, no such item was known to any individual designated in 37 CFR § 1.56(c), more than three months prior to the filing of this statement.

DEPOSIT ACCOUNT

If a fee is due, attached is a check in the amount of \$_____. However, the Commissioner is hereby authorized to charge fees under 37 CFR § 1.16 and § 1.17 which may be required to facilitate this filing, or credit any overpayment to Deposit Account #13-3402. Two copies of this paper are attached for this purpose.

Respectfully submitted,

Anthony J. Zelano, Reg. No. 27,969
Attorney/Agent for Applicants

MILLEN, WHITE, ZELANO
& BRANIGAN, P.C.
Arlington Courthouse Plaza 1
2200 Clarendon Blvd. Suite 1400
Arlington, Virginia 22201
Telephone: (703) 243-6333
Facsimile: (703) 243-6410

Attorney Docket No.: UNIMID-4

Date: October 16, 2002
AJZ:jr



Please type a plus sign (+) inside this box →



PTO/SB/08A (08-00)

Approved for use through 10/31/2002 OMB 0651-0031
U.S. Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/936.565
		Filing Date	February 4, 2002
		First Named Inventor	John J. SAUK
		Group Art Unit	1646
		Examiner Name	Unassigned
Sheet 1 of 1	Attorney Docket Number	UNIMD-4	

RECEIVED

OCT 17 2002

TECH CENTER 1600/2900

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		Geng HU et al. "Endoplasmic Reticulum Protein Hsp47 Binds Specifically to the N-Terminal Globular Domain of the Amino-Propeptide of the Procollagen 1 α 1(I)-Chain," JOURNAL OF CELLULAR BIOCHEMISTRY, Vol. 59, pp. 350-367, 1995	
		Timothy SMITH et al. "Hsp47 And Cyclophilin B Traverse the Endoplasmic Reticulum with Procollagen into Pre-Golgi Intermediate Vesicles," THE JOURNAL OF BIOLOGICAL CHEMISTRY, Vol. 270, No. 31, Issue of August 4, 1995, pp. 18323-18328	
		Luciano R. FERREIRA et al., "Hsp47 And Other ER-Resident Molecular Chaperones Form Heterocomplexes With Each Other and With Collagen Type IV Chains," CONNECTIVE TISSUE RESEARCH 1996, Vol. 33, No. 4, pp. 265-273.	
		Hessam SIAVASH et al., "Inhibition of Cysteine Proteinases by Autolytic Digestion is Mediated by CBP2/Hsp47," CONNECTIVE TISSUE RESEARCH, Vol. 43, pp. 1-6, 2002	
		Carla HERBERT et al., "Cell Surface Colligin/Hsp47 Associates With Tetraspanin Protein CD9 in Epidermoid Carcinoma Cell Lines," JOURNAL OF CELLULAR BIOCHEMISTRY, Vol. 73, pp. 248-258, 1999	
		Ricardo Della COLETTA et al., "Increase in Expression of Hsp47 And Collagen in Hereditary Gingival Fibromatosis is Modulated by Stress And Terminal Procollagen N-Propeptides," CONNECTIVE TISSUE RESEARCH, Vol. 40(4), pp. 237-249, 1999	
		Carla HERBERT et al., "Non-Natural CBP2 Binding Peptides and Peptomers Modulate Carcinoma Cell Adhesion and Invasion," JOURNAL OF CELLULAR BIOCHEMISTRY, Vol. 82, pp. 145-154, 2001	
		John J. SAUK et al., "Binding Motifs of CBP2 A Potential Cell Surface Target for Carcinoma Cells," JOURNAL OF CELLULAR BIOCHEMISTRY, Vol. 78, pp. 261-263, 2000	
		Search Results on HSP47	
		Abstract of KOIDE et al., J. BIOL. CHEM., 2002 February 22, 277(8), 6178-82	

Examiner Signature	Date Considered
--------------------	-----------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

* Unique citation designation number: Applicant is to place a check mark here if English language Translation is attached

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.